10-Q: Solsence Reports Revenue Drop, Net Loss Amidst Inventory Accounting Issues

Solsence, Inc. filed its Q2 2026 10-Q, revealing a substantial decrease in revenue and a net loss, compounded by a material weakness in inventory cost accounting.

Summary

• Solsence, Inc. reported a net loss of $1.12 million for the six months ended June 30, 2026, a significant downturn from a net income of $3.58 million in the same period of 2025.
• Total revenue for the six months ended June 30, 2026, decreased to $28.29 million from $34.98 million in the prior year's comparable period.
• The company identified a material weakness in its internal control over financial reporting related to inventory cost accounting, leading to the restatement of previously issued financial statements.
• A settlement agreement with Refy Beauty Ltd. for $938,000 was recognized as a liability in June 2026, impacting the current liabilities.
• Despite the challenges, the company is implementing remediation measures for the identified internal control weaknesses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant revenue decline, a net loss, and the disclosure of a material weakness in internal controls, despite efforts to address these issues.

Positives

• The company is actively implementing remediation measures to address the material weakness in inventory costing.
• Despite a decrease in revenue, cost of revenue also decreased, and the company noted improved production efficiency in 2026.
• Research and development expenses remained relatively flat, indicating continued investment in core technologies.
• The company has a significant federal net operating loss carryforward of approximately $36.9 million as of December 31, 2025, which could offset future taxable income.

Negatives

• Total revenue for the six months ended June 30, 2026, decreased by 19.1% to $28.29 million compared to $34.98 million in the same period of 2025.
• The company reported a net loss of $1.12 million for the six months ended June 30, 2026, compared to a net income of $3.58 million in the prior year.
• A material weakness in internal control over financial reporting related to inventory cost accounting was identified, requiring restatement of prior financial statements.
• Inventories, net, decreased to $12.96 million as of June 30, 2026, from $14.96 million as of December 31, 2025, partly due to restatement adjustments.
• Current liabilities increased significantly to $26.01 million as of June 30, 2026, from $13.93 million as of December 31, 2025, partly due to the Refy settlement liability.

Risks

• The company's dependence on a limited number of key customers poses a risk, as a decision by a customer to cancel a purchase order or supply agreement could significantly impact revenue.
• Potential inability to obtain working capital when needed on acceptable terms or at all is a significant risk.
• The company faces risks related to obtaining materials at costs that can be passed through to customers, including rare earth elements and high purity zinc.
• Uncertain demand for and acceptance of its Solsence products and advanced materials could impact future sales.
• The company's manufacturing capacity and product mix flexibility in light of customer demand present a potential challenge.
• Changes in development and distribution relationships could negatively affect the business.
• The impact of competitive products and technologies is a constant risk in the consumer health and beauty markets.
• The company's reliance on patents and protection of proprietary information is critical for its competitive advantage.

Future Outlook

The company expects that capital spending for 2026 will be between $0.5 million and $1.5 million, funded by operations, existing credit lines, and potential new debt financing. Future capital requirements will depend on customer acceptance, R&D progress, manufacturing expansion, and market development. The company anticipates that supplier price increases and wage inflation may materially affect operations and financial position in 2026 and beyond, and will attempt to pass these costs to customers.

Management Comments

• Management is in the process of evaluating and preparing amendments and restatements of its previously issued financial statements to correct inventory costing errors.
• Management believes that the condensed consolidated financial statements included in this report fairly present the Company's financial position, results of operations, and cash flows.
• Management has begun implementing remediation measures to address the material weakness, including reassessing inventory costing methodologies and enhancing management review controls.

Industry Context

StockSavvy.ai notes that the consumer health and beauty sector, particularly in advanced materials and personal care ingredients, is highly competitive. Solsence's focus on proprietary technologies and SPF-infused products positions it within a growing market, but the reported revenue decline and operational challenges highlight the intense competition and the need for robust financial controls.

Comparison to Industry Standards

• The revenue decline of 19.1% for the six-month period is concerning when compared to the general growth trends in the consumer health and beauty market, which often sees mid-to-high single-digit growth.
• The identification of a material weakness in inventory accounting is a significant deviation from industry best practices, where accurate and reliable financial reporting is paramount.
• The company's reliance on a few large customers (66% of revenue in Q2 2026) is higher than typical for diversified players in the advanced materials sector, where a broader customer base is often preferred to mitigate risk.

Corporate Governance

Legal Proceedings

• Solsence, LLC entered into a Settlement Agreement and Release with Refy Beauty Ltd. on July 6, 2026, to resolve disputes related to certain consumer care products. The settlement involves a payment of $938,000, payable in installments, with a portion potentially credited against future purchases if a new SPF product agreement is reached.

Related Party Transactions

• Outstanding balances associated with related parties include $13.29 million with Beachcorp, LLC and $1.00 million with Strandler, LLC as of June 30, 2026.
• The company has lines of credit and debt agreements with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, a majority shareholder.
• Interest expense related to these parties was $279,000 for the three months ended June 30, 2026, and $542,000 for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders may be negatively impacted by the revenue decline, net loss, and the material weakness in internal controls, which could affect stock valuation.
• Creditors and lenders may be concerned about the increased current liabilities and the company's ability to manage its debt obligations, especially given the related-party nature of significant financing.
• Customers may be affected by potential price increases due to inflation and the company's efforts to pass on costs.
• Suppliers may face challenges if the company's financial performance deteriorates, potentially impacting payment terms.

Next Steps

• Management is implementing remediation measures to address the material weakness in inventory costing.
• The company expects to file amendments to its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q to correct previously issued financial statements.
• The company will continue to monitor and manage its capital expenditures for 2026, which are expected to be between $0.5 million and $1.5 million.
• The company will seek to pass through cost increases to customers to mitigate the impact of inflation.

Key Dates

Recommendation

The significant revenue decline, coupled with a net loss and a material weakness in internal controls requiring restatements, presents substantial risks. While remediation efforts are underway, the financial performance and control environment issues suggest a negative outlook for the stock in the near to medium term.

Keywords

consumer health, skin health, advanced materials, personal care ingredients, inventory accounting, revenue decline, net loss, settlement agreement